Hansoh Pharmaceutical Group Company Limited (HKG: 3692)

Market Cap	105.99B
Revenue (ttm)	13.00B
Net Income (ttm)	5.07B
Shares Out	5.93B
EPS (ttm)	0.81
PE Ratio	21.93
Forward PE	24.70
Dividend	0.40 (2.34%)
Ex-Dividend Date	Sep 20, 2024

Volume	9,068,500
Open	17.80
Previous Close	17.86
Day's Range	17.76 - 18.80
52-Week Range	11.18 - 22.80
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2024

About Hansoh Pharmaceutical Group Company

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameini...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,123
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3692

Financial Performance

In 2023, Hansoh Pharmaceutical Group Company's revenue was 10.10 billion, an increase of 7.69% compared to the previous year's 9.38 billion. Earnings were 3.28 billion, an increase of 26.85%.

Financial numbers in CNY